Skip to content
value.today

Myomo, Inc.

MYO
$47 Mmarket cap on Oct 28, 2026-58.8% since Jan 2024
Compare
World rank
#21,515
Revenue
$41 M
For year ending December-2025
Net income
$-16 M
-38.0% margin
SEC filing
Employees
—

Myomo, Inc. in brief

Myomo, Inc. is a listed company in the Medical Devices industry, based in Boston, Massachusetts, USA. Its market value was $47 M on 28 October 2026, which makes it the 21,515th largest listed company in the world and the 3,886th largest in the USA on this site. In the year to December 2025 it had sales of $41 M and a net loss of $16 M. Paul R. Gudonis is its chief executive. Its shares trade under the symbol MYO (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Myomo, Inc.

We are a wearable medical robotics company that offers functional improvement for those with neuromuscular disorders and upper limb paralysis. We develop and market the MyoPro product line. A MyoPro is a myoelectric-controlled upper limb brace, or orthosis. The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living, or ADLs, in the home and community. It is custom-fabricated by trained professionals during a custom fabrication process for each individual user to meet their specific needs. Our products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. We primarily provide devices directly to patients and bill their insurance companies directly, a sales channel we refer to as direct billing. Under direct billing, we evaluate, measure and fit the MyoPro devices using our own clinical staff or as circumstances dictate, utilize the clinical consulting services of orthotics and prosthetics, or O&P. We also sell our products through various other sales channels, including through O&P providers, which we expect to be a larger contributor to revenue in the future, the Veterans Administration, or VA, and to certain accounts and geographic markets outside the United States. We operate as one business segment.

From the company's annual report filed with the US SEC: read the report

Myomo, Inc. timeline

3 events, 2006–2025
  1. 2006
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2017
  4. 🔔
    · approximate
    Initial public offering on NYSE
  5. 2025
  6. 💰
    Record revenue of $41 million
    FY2025, the highest of the 8 years on record.

Events of Myomo, Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$31 M$62 M$92 M$123 M2023202420252026

World rank over time

▲ up 4,974 places since 2022
2022-01-07: #26538#26,53820222022-12-25: #33469#33,46920222023-07-30: #30491#30,49120232024-01-05: #20772#20,77220242026-03-08: #11572#11,57220262026-08-01: #18546#18,54620262026-10-08: #20826#20,82620262026-10-28: #21564#21,5642026

Rank in USA: #4,920 (Jan 2022) · #5,847 (Dec 2022) · #5,293 (Jul 2023) · #3,607 (Jan 2024) · #2,243 (Mar 2026) · #3,618 (Aug 2026) · #3,772 (Oct 2026) · #3,890 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
1.0×
Price / book
4.1×
Free cash flow yield
-34.6%
Net margin (TTM)
-33.1%
Operating margin
-35.2%
Return on equity
-132.2%
Liabilities / assets
70.5%
Net debt
$-3M
Revenue growth
+25.7%
R&D / revenue
17.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $2M, net income $-10M$2MFY18Fiscal year ending Dec 2019: revenue $4M, net income $-11M$4MFY19Fiscal year ending Dec 2020: revenue $8M, net income $-12M$8MFY20Fiscal year ending Dec 2021: revenue $14M, net income $-10M$14MFY21Fiscal year ending Dec 2022: revenue $16M, net income $-11M$16MFY22Fiscal year ending Dec 2023: revenue $19M, net income $-8M$19MFY23Fiscal year ending Dec 2024: revenue $33M, net income $-6M$33MFY24Fiscal year ending Dec 2025: revenue $41M, net income $-16M$41MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$41M+25.7%$-14M$-16M-38.0%
Dec 2024$33M+69.2%$-6M$-6M-19.0%
Dec 2023$19M+23.7%$-8M$-8M-42.4%
Dec 2022$16M+12.3%$-11M$-11M-68.9%
Dec 2021$14M+82.8%$-10M$-10M-74.8%
Dec 2020$8M+97.4%$-11M$-12M-152.5%
Dec 2019$4M+57.4%$-11M$-11M-278.9%
Dec 2018$2M—$-11M$-10M-423.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-15M$2M$-16M$-0.37—
Dec 2024$-3M$1M$-5M$-0.16—
Dec 2023$-6M$0M$-6M$-0.28—
Dec 2022$-10M$0M$-10M$-1.52—
Dec 2021$-10M$0M$-10M$-1.89—
Dec 2020$-9M$0M$-9M$-3.67—
Dec 2019$-10M$0M$-10M$-20.79—
Dec 2018$-10M$0M$-10M$-25.18—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$46M
Net income, trailing 12 months
$-15M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $12M, net income $-0M$12MDec ’24Three months to Mar 2025: revenue $10M, net income $-3M$10MMar ’25Three months to Jun 2025: revenue $10M, net income $-5M$10MJun ’25Three months to Sep 2025: revenue $10M, net income $-4M$10MSep ’25Three months to Dec 2025 (from the annual report): revenue $11M, net income $-4M$11MDec ’25Three months to Mar 2026: revenue $10M, net income $-3M$10MMar ’26Three months to Jun 2026: revenue $12M, net income $-4M$12MJun ’26Three months to Sep 2026: revenue $12M, net income $-4M$12MSep ’26

Latest quarter to Sep 2026: revenue $12M (+22.2% on a year earlier), net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Myomo, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$41 M
Operating income
$-14 M
Net income
$-16 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$39 M
Total liabilities
$27 M
Total equity
$11 M

As of December-2025

Top 66 institutional investors in Myomo, Inc.#

As of Sep 30, 2026
66 institutions held 10.6 M shares (about 26.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 20.5%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Myomo, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Rosalind Advisors, Inc.3,917,886+280,000 (+7.70%)9.77%$6 MNov 16, 2026
2Vanguard Capital Management LLC1,636,5700 (0.00%)4.08%$3 MNov 13, 2026
3Clearstead Advisors, LLC425,600-9 (0.00%)1.06%$1 MNov 6, 2026
4Two Sigma Investments, LP388,107New0.97%$1 MNov 16, 2026
5Jane Street Group, LLC380,802-215,550 (-36.14%)0.95%$1 MNov 12, 2026
6Geode Capital Management, LLC350,490+6,073 (+1.76%)0.87%$1 MNov 6, 2026
7Morgan Stanley330,944+324,320 (+4896.14%)0.83%$1 MNov 13, 2026
8Palumbo Wealth Management LLC278,354-21,422 (-7.15%)0.69%$0 MNov 13, 2026
9Gsa Capital Partners LLP252,663-19,213 (-7.07%)0.63%$0 MNov 16, 2026
10Millennium Management LLC247,380-23,914 (-8.81%)0.62%$0 MNov 16, 2026
11Vanguard Fiduciary Trust Co246,139+38,462 (+18.52%)0.61%$0 MNov 13, 2026
12Marshall Wace, LLP222,755New0.56%$0 MNov 13, 2026
13AQR Capital Management LLC207,782-720,486 (-77.62%)0.52%$0 MNov 16, 2026
14Arrowstreet Capital, Limited Partnership180,629New0.45%$0 MNov 13, 2026
15LPL Financial LLC153,100-154,900 (-50.29%)0.38%$0 MNov 6, 2026
16BlackRock, Inc.136,261-86,956 (-38.96%)0.34%$0 MNov 13, 2026
17Citadel Advisors LLC109,786+7,268 (+7.09%)0.27%$0 MNov 16, 2026
18Centiva Capital, LP108,606+22,610 (+26.29%)0.27%$0 MNov 13, 2026
19State Street Corp105,8750 (0.00%)0.26%$0 MNov 12, 2026
20Renaissance Technologies LLC101,700+53,200 (+109.69%)0.25%$0 MNov 12, 2026
21Northern Trust Corp80,6090 (0.00%)0.20%$0 MNov 16, 2026
22Acadian Asset Management LLC74,392New0.19%$0 MNov 9, 2026
23XTX Topco Ltd68,600-41,428 (-37.65%)0.17%$0 MNov 16, 2026
24Stratos Wealth Partners, LTD.60,0000 (0.00%)0.15%$0 MNov 13, 2026
25Quadrature Capital Ltd57,956New0.14%$0 MNov 13, 2026
Show all 66: investors 26 to 66
Institutional investors 26 to 66 in Myomo, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Goldman Sachs Group Inc56,830-38,018 (-40.08%)0.14%$0 MNov 16, 2026
27Bridgeway Capital Management, LLC42,519New0.11%$0 MNov 16, 2026
28Empowered Funds, LLC39,619New0.10%$0 MNov 13, 2026
29Accel Wealth Management39,0820 (0.00%)0.10%$0 MOct 13, 2026
30FMR LLC28,638-971 (-3.28%)0.07%$0 MNov 10, 2026
31IMC-Chicago, LLC26,328+5,854 (+28.59%)0.07%$0 MNov 5, 2026
32Summit Financial Strategies, Inc.25,0000 (0.00%)0.06%$0 MOct 14, 2026
33Accurate Wealth Management, LLC21,1200 (0.00%)0.05%$0 MOct 20, 2026
34Cerity Partners LLC19,418-25,880 (-57.13%)0.05%$0 MNov 13, 2026
35Ieq Capital, LLC16,725-111,024 (-86.91%)0.04%$0 MNov 10, 2026
36Qube Research & Technologies Ltd14,202-53,562 (-79.04%)0.04%$0 MNov 13, 2026
37Abel Hall, LLC12,927-337 (-2.54%)0.03%$0 MOct 19, 2026
38StoneX Group Inc.11,842New0.03%$0 MNov 3, 2026
39Prudential Financial Inc11,400New0.03%$0 MNov 16, 2026
40Vanguard Global Advisers, LLC10,8700 (0.00%)0.03%$0 MNov 13, 2026
41Jpmorgan Chase & Co9,888-18,842 (-65.58%)0.02%$0 MNov 12, 2026
42UBS Group AG7,090-406,589 (-98.29%)0.02%$0 MNov 10, 2026
43Arax Advisory Partners5,710-10,884 (-65.59%)0.01%$0 MNov 12, 2026
44Osaic Holdings, Inc.5,045+45 (+0.90%)0.01%$0 MNov 12, 2026
45Royal Bank Of Canada4,575-3,601 (-44.04%)0.01%$0 MNov 16, 2026
46Nisa Investment Advisors, LLC4,2180 (0.00%)0.01%$0 MOct 20, 2026
47PNC Financial Services Group, Inc.4,131-1,001 (-19.51%)0.01%$0 MNov 6, 2026
48Federation des caisses Desjardins du Quebec3,0000 (0.00%)0.01%$0 MNov 16, 2026
49Russell Investments Group, Ltd.2,831+335 (+13.42%)0.01%$0 MNov 6, 2026
50SBI Securities Co., Ltd.2,451+1,320 (+116.71%)0.01%$0 MOct 22, 2026
51Ameritas Advisory Services, LLC2,0000 (0.00%)0.01%$0 MNov 12, 2026
52Bollard Group LLC1,5700 (0.00%)0.00%$0 MNov 13, 2026
53Group One Trading LLC1,409-100 (-6.63%)0.00%$0 MNov 10, 2026
54EverSource Wealth Advisors, LLC1,018-1,561 (-60.53%)0.00%$0 MNov 4, 2026
55BNP Paribas Financial Markets884-138,310 (-99.36%)0.00%$0 MNov 12, 2026
56Essential Partners LLC639-1,136 (-64.00%)0.00%$0 MOct 14, 2026
57NewEdge Advisors, LLC5470 (0.00%)0.00%$0 MNov 13, 2026
58Allworth Financial LP370-2,214 (-85.68%)0.00%$0 MNov 17, 2026
59Jones Financial Companies Lllp200New0.00%$0 MNov 13, 2026
60GAMMA Investing LLC1520 (0.00%)0.00%$0 MOct 8, 2026
61True Wealth Design, LLC98-380 (-79.50%)0.00%$0 MOct 13, 2026
62IFP Advisors, Inc67-96 (-58.90%)0.00%$0 MOct 16, 2026
63Nuveen, LLC57-10,172 (-99.44%)0.00%$0 MNov 10, 2026
64Rothschild Investment LLC33-541 (-94.25%)0.00%$0 MNov 10, 2026
65Farther Finance Advisors, LLC8-436 (-98.20%)0.00%$0 MOct 8, 2026
66Caitong International Asset Management Co., Ltd50 (0.00%)0.00%$0 MOct 29, 2026

Mutual funds holding Myomo, Inc.#

15 funds hold shares worth $2 M (about 5.5% of the company). Since their previous reports 9 added shares and 33 sold, selling $1 M net.
Mutual funds holding Myomo, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.24 M$1 M3.1%<0.01%+47%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.372,587$0 M0.93%<0.01%+26%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC219,059$0 M0.55%<0.01%+24%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.180,461$0 M0.45%<0.01%+4.1%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC47,667$0 M0.12%<0.01%+16%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC45,583$0 M0.11%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.31,752$0 M0.08%<0.01%+3.3%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.21,739$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company13,237$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC10,229$0 M0.03%<0.01%−94%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC6,508$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC1,694$0 M<0.01%<0.01%+11%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC1,334$0 M<0.01%<0.01%−39%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC1,324$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.203$0 M<0.01%<0.01%+18%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 15 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Myomo, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$439 K
11 purchases, 3 insiders
Sold, 12 months
$103 K
5 sales, 2 insiders
Net, 12 months
$336 K
open market only
Insiders on file
18
since
$390 K-$413 K$0Nov 2023: bought $155 K (1 trades), sold $0 (1 trades)Nov 23Dec 2023: bought $0 (0 trades), sold $0 (2 trades)Mar 2024: bought $175 K (1 trades), sold $0 (0 trades)MarMay 2024: bought $175 K (1 trades), sold $131 K (1 trades)Sep 2024: bought $0 (0 trades), sold $33 K (2 trades)SepMar 2025: bought $37 K (1 trades), sold $413 K (2 trades)May 2025: bought $390 K (4 trades), sold $78 K (1 trades)MayAug 2025: bought $160 K (3 trades), sold $0 (0 trades)Nov 2025: bought $9 K (4 trades), sold $0 (0 trades)NovMar 2026: bought $116 K (3 trades), sold $0 (0 trades)May 2026: bought $267 K (5 trades), sold $32 K (2 trades)MayJun 2026: bought $51 K (1 trades), sold $0 (0 trades)Aug 2026: bought $0 (0 trades), sold $30 K (1 trades)AugSep 2026: bought $0 (0 trades), sold $41 K (2 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Myomo, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed David A. HenryChief Financial OfficerGrant or award+51,250——549,862Form 4
filed Paul R. GudonisChief Executive Officer, DirectorGrant or award+71,250——1.51 MForm 4
filed Harry KovelmanChief Medical OfficerGrant or award+32,500——122,389Form 4
filed Mary-Katherine Hale McClureChief Commericial OfficerGrant or award+275,000——275,000Form 4
filed David A. HenryChief Financial OfficerShares withheld for tax-3,133$1.370$4 K498,612Form 4
filed Paul R. GudonisChief Executive Officer, DirectorGrant or award+8,363——1.44 MForm 4
filed David A. HenryChief Financial OfficerGrant or award+6,272——501,745Form 4
filed Harry KovelmanChief Medical OfficerSellamended-15,844$1.271$20 K89,889Form 4/A

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Myomo, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.2 M
3.0% of shares · 5.75 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-16 reverse split

Fails to deliver

  • : 12,663 shares at $1.17
  • : 12,920 shares at $1.21
  • : 178 shares at $1.26
  • : 7,920 shares at $1.45
  • : 2,782 shares at $1.57

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Myomo, Inc. scorecard#

Passes 9 of the 22 checks that could be worked out: strongest in growth (4 of 6), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median4.1×Price to book 4.1× against Medical Devices's median of 2.5×.
    • ✓Price to sales below its peers' median1.0×Price to sales 1.0× against Medical Devices's median of 2.4×.
    • ✗Free cash flow yield above 5%-34.6%Free cash flow is -34.6% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 6
    • ✓Revenue grew in the newest year25.8%Revenue up 25.8% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years38.0%38.0% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median38.0%38.0% a year against Medical Devices's median of 10.8% (73 companies).
    • ✗Earnings per share grew in the newest year-0.37 vs -0.16Diluted EPS -0.37 in fiscal 2025 against -0.16 the year before (report's currency).
    • ✗Net income higher than five years earlier-$16 M-$16 M in fiscal 2025 against -$12 M in 2020.
    • ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$16 MNet income -$16 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-35.2%-35.2% against Medical Devices's median of -8.2% (86 companies).
    • ✗Return on equity above 15%-86.2%-86.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-35.2%-35.2% in fiscal 2025 against -68.6% in 2022.
  • Financial health3 of 5
    • ✓Short-term assets cover short-term liabilities3.3×Current ratio 3.30 at the end of fiscal 2025.
    • ✓Debt below equity1.0×Debt to equity 0.98 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $3 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-2.84Z-score -2.84 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year10.8%Diluted shares up 10.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Myomo, Inc.'s statements, beside the median of Medical Devices.

Myomo, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-35.2%-8.2%
Net margin-38.0%-10.4%
Return on equity-86.2%-16.8%
Revenue growth, 3 years a year38.0%10.8%
Revenue growth25.8%10.4%
Debt to equity0.98×0.64×

3of 9on the Piotroski tests of financial strength

  • Net loss of $16 million, the 10th loss-making year in a row.
  • Free cash flow was negative: -$16 million.
  • The share count rose 10.8% in the year.
  • Revenue has grown 9 years in a row.

Myomo, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Myomo, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue41331916147.63.82.41.61.1
Cost of revenue149.46.15.33.52.61.4r0.70.50.3
Gross profit27231310105.02.4r1.71.10.8
Research and development6.94.82.62.52.61.71.7r1.81.81.1
Selling, general and administrative——1918181411r105.83.0
Selling and marketing20129.0———————
General and administrative14129.7———————
Operating expenses41292121211513r127.64.1
Operating income−14−6.2−8.2−11−10−11−11−11−6.5−3.3
Interest expense and finance costs—————0.20.1———
Other non-operating income (expense)−0.70.40.20.0−0.0−1.10.10.2−5.5−0.3
Income before tax−15−5.8−8.0−11−10−12————
Income tax0.50.40.20.10.1———00
Net income including minority interests−16−6.2−8.1−11−10−12−11−10−12—
Minority interests' share of net income——————−12———
Net income attributable to shareholders−16−6.2−8.1−11−10−12−11−10−12−3.6
Earnings per share, basic-0.37-0.16-0.28-1.52-1.89-3.67-20.79r-25.18r-2.93-4.13
Earnings per share, diluted-0.37-0.16-0.28-1.52-1.89-3.67-20.79r-25.18r-2.93-4.13
Shares, weighted average (basic)4238297.15.8—————
Shares, weighted average (diluted)4238297.15.83.30.60.4r4.31.1
Balance sheet
Cash and cash equivalents14246.95.316124.56.5130.8
Short-term investments4.30.52.00——————
Receivables4.13.82.41.92.00.90.40.40.30.1
Inventory3.13.21.81.40.80.70.40.30.20.1
Other current assets1.90.90.60.60.8r0.60.80.70.40.2
Current assets2833149.219r146.17.9141.1
Property, plant and equipment2.21.30.20.20.30.10.20.20.10.0
Right-of-use (leased) assets6.77.60.70.50.60.2————
Total assets3942151020156.68.3141.7
Accounts payable1.1r1.21.10.60.70.20.50.40.30.3
Debt due within a year0r3.0r————1.8———
Current liabilities8.3105.53.64.32.93.91.91.53.0
Long-term debt——————0.9———
Lease liabilities (non-current)7.77.40.10.20.40.2————
Non-current liabilities—————————3.5
Total liabilities27185.63.84.73.14.81.91.56.5
Retained earnings−119−103−97−89−78−68−56−45−35−23
Shareholders' equity11259.06.415126.4r6.412−18
Total liabilities and equity3942151020156.68.3141.7
Shares outstanding3834r277.86.94.60.60.4r111.1
Cash-flow statement
Share-based compensation2.10.91.11.21.10.60.90.80.30.1
Cash from operating activities−15−3.3−6.2−10−9.5−9.0−10−9.6−6.2−3.2
Capital expenditure−1.7−1.4−0.1−0.1−0.3−0.0−0.1−0.1−0.1−0.0
Cash from investing activities−7.10.3−2.0−0.3−0.3−0.0−0.1−0.1−0.1−0.0
Debt issued3.00————2.8———
Debt repaid−4.00———−1.7————
Shares issued————1.1———10—
Cash from financing activities11219.70.413178.33.3183.0
Change in cash−10181.5−103.37.7−2.1−6.412−0.2
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Myomo, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.

Myomo, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office—
🇩🇪 Germany1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Myomo, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.2 M
Paul Gudonis
Other top executives, average
$649 K
the CEO earned 1.9× this
$100 invested is now
$178
Myomo, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Paul Gudonis$1.2 M−$349 K$649 K$178
2024Paul Gudonis$1.2 M$1.5 M$740 K$1259
2023Paul Gudonis$664 K$2.1 M$479 K$980

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Myomo, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Debt called earlyFiling

Auditor changed 1 · Debt called early 1 · Directors and officers 6 · Material agreement 5 · New debt 3 · Unregistered share sale 1 · Bylaws or fiscal year changed 2 · Shareholder vote 4 · Results announced 12

Myomo, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K/A
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Material agreementNew debtUnregistered share saleResults announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Auditor changedDirectors and officers8-K
Results announced8-K
Debt called earlyMaterial agreement8-K
Material agreement8-K
Results announced8-K
Material agreementNew debt8-K
Results announced8-K
Material agreementNew debt8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Myomo, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2014$2 MIssued in a merger or acquisitionUnder $2 million37equitySEC
Sep 2012$7 MNo. 1$2 to $10 million33equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Myomo, Inc.#

$0 spent on lobbying the US Congress and federal agencies in 2022.

Lobbying, 2022
$0
#1,471 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2022
2026 so far
—

Lobbying firms hired in 2022

A10 Associates, LLC

Myomo, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2022$0—3
2021$0—4
2020$240 K—4
2019$332 K—11
2018$80 K—5

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Myomo, Inc.” and “A10 Associates on behalf of Myomo, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How Myomo, Inc. compares in Medical Devices

  • Market cap$47 M · higher than 25% of 142
  • Revenue$41 M · higher than 26% of 155
  • Net margin-33.1% · higher than 31% of 144
  • Revenue growth25.8% · higher than 79% of 104
  • Price / sales1.0× · lower than 81% of 96
  • Price / book4.1× · lower than 36% of 99
  • FCF yield-34.6% · higher than 21% of 76

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
Myomo, Inc.🇺🇸$47 M—-33.1%+25.8%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Myomo, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Myomo, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Myomo, Inc.? Suggest a correction